EP2509629A4 - Dock-and-lock (dnl) complexes for delivery of interference rna - Google Patents

Dock-and-lock (dnl) complexes for delivery of interference rna

Info

Publication number: EP2509629A4
Authority: EP; European Patent Office
Prior art keywords: dnl; dock; complexes; lock; delivery
Prior art date: 2009-12-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP10836672.5A

Other languages

German (de)

French (fr)

Other versions

EP2509629A1 (en

Inventor

Chien-Hsing Chang

David M Goldenberg

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

IBC Pharmaceuticals Inc

Original Assignee

IBC Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-09

Filing date

2010-12-09

Publication date

2013-06-26

2009-12-22 Priority claimed from US12/644,146 external-priority patent/US7981398B2/en

2010-03-25 Priority claimed from US12/731,781 external-priority patent/US8003111B2/en

2010-04-01 Priority claimed from US12/752,649 external-priority patent/US8034352B2/en

2010-04-06 Priority claimed from US12/754,740 external-priority patent/US8562988B2/en

2010-08-27 Priority claimed from US12/869,823 external-priority patent/US20110020273A1/en

2010-08-30 Priority claimed from US12/871,345 external-priority patent/US8551480B2/en

2010-10-29 Priority claimed from US12/915,515 external-priority patent/US20110064754A1/en

2010-11-18 Priority claimed from US12/949,536 external-priority patent/US8211440B2/en

2010-12-09 Application filed by IBC Pharmaceuticals Inc filed Critical IBC Pharmaceuticals Inc

2012-10-17 Publication of EP2509629A1 publication Critical patent/EP2509629A1/en

2013-06-26 Publication of EP2509629A4 publication Critical patent/EP2509629A4/en

Status Withdrawn legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific

EP10836672.5A 2009-12-09 2010-12-09 Dock-and-lock (dnl) complexes for delivery of interference rna Withdrawn EP2509629A4 (en)

Applications Claiming Priority (12)

Application Number	Priority Date	Filing Date	Title
US26787709P	2009-12-09	2009-12-09
US12/644,146 US7981398B2 (en)	2005-04-06	2009-12-22	PEGylation by the dock and lock (DNL) technique
US30268210P	2010-02-09	2010-02-09
US12/731,781 US8003111B2 (en)	2005-04-06	2010-03-25	Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
US12/752,649 US8034352B2 (en)	2005-04-06	2010-04-01	Tetrameric cytokines with improved biological activity
US12/754,740 US8562988B2 (en)	2005-10-19	2010-04-06	Strategies for improved cancer vaccines
US12/869,823 US20110020273A1 (en)	2005-04-06	2010-08-27	Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
US12/871,345 US8551480B2 (en)	2004-02-13	2010-08-30	Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US12/915,515 US20110064754A1 (en)	2005-03-03	2010-10-29	Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
US41459210P	2010-11-17	2010-11-17
US12/949,536 US8211440B2 (en)	2005-10-19	2010-11-18	Multivalent immunoglobulin-based bioactive assemblies
PCT/US2010/059660 WO2011072114A1 (en)	2009-12-09	2010-12-09	Dock-and-lock (dnl) complexes for delivery of interference rna

Publications (2)

Publication Number	Publication Date
EP2509629A1 EP2509629A1 (en)	2012-10-17
EP2509629A4 true EP2509629A4 (en)	2013-06-26

Family

ID=44145910

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP10836672.5A Withdrawn EP2509629A4 (en)	2009-12-09	2010-12-09	Dock-and-lock (dnl) complexes for delivery of interference rna

Country Status (5)

Country	Link
EP (1)	EP2509629A4 (en)
CN (1)	CN102665758A (en)
AU (1)	AU2010328136B2 (en)
CA (1)	CA2781717C (en)
WO (1)	WO2011072114A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102949729B (en) *	2012-11-20	2014-06-18	中国科学院宁波材料技术与工程研究所	Active targeting type small interfering ribonucleic acid (siRNA) delivery carrier and preparation method thereof
MX2016014881A (en)	2014-05-14	2017-05-01	Alex Levitzki Man And Holdings Ltd	Improved polyethyleneimine polyethyleneglycol vectors.
WO2016037985A1 (en) *	2014-09-08	2016-03-17	Ruprecht-Karls-Universität Heidelberg	Construct for the delivery of a molecule into the cytoplasm of a cell
US10828381B2 (en) *	2015-04-17	2020-11-10	University Of Kentucky Research Foundation	RNA nanoparticles and method of use thereof
CN105168151B (en) *	2015-08-07	2017-10-24	哈尔滨工业大学	A kind of preparation method of isotope of redox-sensitive type nano target carrier
CN112725340A (en) *	2021-01-22	2021-04-30	佛山科学技术学院	Small molecule interference ribonucleic acid and its recombinant adenovirus and application
WO2022206781A1 (en) *	2021-03-30	2022-10-06	南京大学	Rna delivery system for treating colitis

Citations (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020040130A1 (en) *	2000-07-10	2002-04-04	Sequenom, Inc.	Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20030232420A1 (en) *	2002-05-03	2003-12-18	Andreas Braun	Kinase anchor protein muteins, peptides thereof and related documents
US20060154330A1 (en) *	2002-09-06	2006-07-13	Enno Klussmann	Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same
WO2006107786A2 (en) *	2005-04-06	2006-10-12	Ibc Pharmaceuticals, Inc.	Improved stably tethered structures of defined compositions with multiple functions or binding specificities
WO2007046893A2 (en) *	2005-10-19	2007-04-26	Ibc Pharmaceuticals, Inc.	Methods for generating bioactive assemblies and uses thereof
WO2007075270A2 (en) *	2005-12-16	2007-07-05	Ibc Pharmaceuticals, Inc.	Multivalent immunoglobulin-based bioactive assemblies
WO2007134037A2 (en) *	2006-05-15	2007-11-22	Immunomedics, Inc.	Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
WO2009055653A1 (en) *	2007-10-26	2009-04-30	Ibc Pharmaceuticals, Inc.	Pegylation by the dock and lock (dnl) technique
US20090202487A1 (en) *	2005-04-06	2009-08-13	Ibc Pharmaceuticals, Inc.	Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
WO2009126558A1 (en) *	2008-04-10	2009-10-15	Ibc Pharmaceuticals, Inc.	Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7527787B2 (en) *	2005-10-19	2009-05-05	Ibc Pharmaceuticals, Inc.	Multivalent immunoglobulin-based bioactive assemblies
WO2005076998A2 (en) *	2004-02-05	2005-08-25	Intradigm Corporation	Rnai therapeutics for treatment of eye neovascularization diseases
US20100008937A1 (en) *	2006-04-25	2010-01-14	Immune Disease Institute, Inc.	Targeted delivery to leukocytes using non-protein carriers

2010
- 2010-12-09 CN CN2010800526905A patent/CN102665758A/en active Pending
- 2010-12-09 CA CA2781717A patent/CA2781717C/en active Active
- 2010-12-09 WO PCT/US2010/059660 patent/WO2011072114A1/en active Application Filing
- 2010-12-09 EP EP10836672.5A patent/EP2509629A4/en not_active Withdrawn
- 2010-12-09 AU AU2010328136A patent/AU2010328136B2/en active Active

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020040130A1 (en) *	2000-07-10	2002-04-04	Sequenom, Inc.	Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20030232420A1 (en) *	2002-05-03	2003-12-18	Andreas Braun	Kinase anchor protein muteins, peptides thereof and related documents
US20060154330A1 (en) *	2002-09-06	2006-07-13	Enno Klussmann	Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same
WO2006107786A2 (en) *	2005-04-06	2006-10-12	Ibc Pharmaceuticals, Inc.	Improved stably tethered structures of defined compositions with multiple functions or binding specificities
US20090202487A1 (en) *	2005-04-06	2009-08-13	Ibc Pharmaceuticals, Inc.	Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
WO2007046893A2 (en) *	2005-10-19	2007-04-26	Ibc Pharmaceuticals, Inc.	Methods for generating bioactive assemblies and uses thereof
WO2007075270A2 (en) *	2005-12-16	2007-07-05	Ibc Pharmaceuticals, Inc.	Multivalent immunoglobulin-based bioactive assemblies
WO2007134037A2 (en) *	2006-05-15	2007-11-22	Immunomedics, Inc.	Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
WO2009055653A1 (en) *	2007-10-26	2009-04-30	Ibc Pharmaceuticals, Inc.	Pegylation by the dock and lock (dnl) technique
WO2009126558A1 (en) *	2008-04-10	2009-10-15	Ibc Pharmaceuticals, Inc.	Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. M. GOLDENBERG ET AL: "Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting", THE JOURNAL OF NUCLEAR MEDICINE, vol. 49, no. 1, 1 January 2008 (2008-01-01), pages 158 - 163, XP055028152, ISSN: 0161-5505, DOI: 10.2967/jnumed.107.046185 *
See also references of WO2011072114A1 *
SONG E ET AL: "Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 23, no. 6, 22 May 2005 (2005-05-22), pages 709 - 717, XP002390626, ISSN: 1087-0156, DOI: 10.1038/NBT1101 *

Also Published As

Publication number	Publication date
AU2010328136A1 (en)	2012-05-17
EP2509629A1 (en)	2012-10-17
WO2011072114A1 (en)	2011-06-16
CA2781717A1 (en)	2011-06-16
CN102665758A (en)	2012-09-12
AU2010328136B2 (en)	2016-02-25
CA2781717C (en)	2017-09-12

Legal Events

Date	Code	Title	Description
2012-09-14	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2012-10-17	17P	Request for examination filed	Effective date: 20120629
2012-10-17	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2013-03-20	DAX	Request for extension of the european patent (deleted)
2013-06-26	A4	Supplementary search report drawn up and despatched	Effective date: 20130527
2013-06-26	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/46 20060101AFI20130521BHEP Ipc: A61K 39/395 20060101ALI20130521BHEP Ipc: C12N 15/113 20100101ALI20130521BHEP
2015-06-03	17Q	First examination report despatched	Effective date: 20150429
2018-03-22	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2018-04-18	INTG	Intention to grant announced	Effective date: 20180323
2018-12-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2019-01-30	18D	Application deemed to be withdrawn	Effective date: 20180803

Publication	Publication Date	Title
HK1252488A1 (en)	2019-05-24	Compositions for nucleic acid delivery
PL2959900T3 (en)	2017-11-30	Compound for treatment of cancer
IL214699A0 (en)	2011-11-30	Insulin formulations for rapid uptake
IL218965A0 (en)	2012-07-31	siRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS
EP2373804A4 (en)	2013-03-13	Compositions for improving gene amplification
EP2470019A4 (en)	2013-03-13	Compositions for delivery of insoluble agents
HK1160034A1 (en)	2012-08-10	Pharmaceutical composition for inhalation
EP2509629A4 (en)	2013-06-26	Dock-and-lock (dnl) complexes for delivery of interference rna
EP2283862A4 (en)	2012-09-26	Antitumor agent
ZA201003844B (en)	2011-03-30	Delivery of functional compounds
GB0918722D0 (en)	2009-12-09	Anti cancer agent
SG2014006860A (en)	2014-05-29	ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION
EP2484385A4 (en)	2013-10-30	Composition for treatment of pancreatic cancer
EP2489351A4 (en)	2013-03-27	Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treament of cancer thereof
EP2250290A4 (en)	2011-12-21	Pttg1 as a biomarker for cancer treatment
GB0917792D0 (en)	2009-11-25	Delivery agent
HUP0800260A2 (en)	2010-03-01	Feed-complementary for meatquality correction
GB0911862D0 (en)	2009-08-19	RNA delivery vehicles
GB0901497D0 (en)	2009-03-11	Compound for therapy
GB0903080D0 (en)	2009-04-08	Compound for therapy
GB0914441D0 (en)	2009-09-30	Compound for therapy
GB0808116D0 (en)	2008-06-11	bioarker for pancreatic cancer
TWM370510U (en)	2009-12-11	Improved structure for wheel
GB0901035D0 (en)	2009-03-11	Bakeable formulation
TWM390728U (en)	2010-10-21	Glass-combined God sedan